Aktie A3DTWN SILO PHARMA, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Silo Pharma, Inc.

Aktien

A3DTWN

US82711P2011

SILO

Verzögert Nasdaq
Andere Börsenplätze
 20:50:43 26.06.2024 		% 5 Tage % 1. Jan.
0,9901 USD -8,32 % Intraday Chart für Silo Pharma, Inc. +0,18 % -31,24 %
07.06. Silo Pharma nähert sich optimaler Formulierung für Ketamin-Implantat MT
07.06. Silo Pharma meldet die erfolgreiche Produktion des Ketamin-Implantats SP-26 gegen Fibromyalgie CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
Certain Common Stock of Silo Pharma, Inc. are subject to a Lock-Up Agreement Ending on 22-JUN-2024.
Silo Pharma, Inc. announced that it has received $2.077409 million in funding
Silo Pharma Close to Achieving Optimal Formulation for Ketamine Implant
Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
Top Midday Decliners
Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Sector Update: Health Care Stocks Rise Tuesday Afternoon
Silo Pharma Submits Pre-Investigational NDA For PTSD, Anxiety Treatment; Shares Rise
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors
Silo Pharma, Inc. announced that it expects to receive $2.077409 million in funding
Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
Silo Pharma, Inc. Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
Silo Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DTWN Aktie
  4. Nachrichten Silo Pharma, Inc.
  5. Andere Sprachen